Silence Therapeutics plc

SLN

US82686Q1013

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
21.21 ^USD	-7.58%		-0.42%	+22.11%

May. 09	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT
Apr. 29	Silence Therapeutics plc Announces Retirement of Alistair Gray from Board of Directors, Effective May 1, 2024	CI

Presenter SpeechMichael Ulz (Analysts)All right. Good morning, everyone. I'm Michael Ulz from ...

This article is reserved for subscribers

Signed up already?

Not subscribed yet?

Latest news about Silence Therapeutics plc

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	May. 09	MT
Silence Therapeutics plc Announces Retirement of Alistair Gray from Board of Directors, Effective May 1, 2024	Apr. 29	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	Apr. 16	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	Apr. 12	MT
Silence Therapeutics plc Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)	Apr. 08	CI
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading	Mar. 27	MT
European Equities Traded in the US as American Depositary Receipts Start Week Slightly Lower in Monday Trading	Mar. 18	MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Friday Trading	Mar. 15	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	Mar. 14	MT
Chardan Boosts Price Target on Silence Therapeutics to $42 From $26 on Positive Data From Zerlasiran Study, Keeps Buy Rating	Mar. 14	MT
Morgan Stanley Boosts Price Target on Silence Therapeutics to $45 From $29, Says Q4 Showed 'Meaningful Progress,' Keeps Overweight Rating	Mar. 14	MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading	Mar. 13	MT
Silence Therapeutics Says Phase 2 Study of High Lipoprotein(a) Treatment Meets Primary Endpoint	Mar. 13	MT
Sector Update: Health Care Stocks Gain Premarket Wednesday	Mar. 13	MT
Transcript : Silence Therapeutics plc, Q4 2023 Earnings Call, Mar 13, 2024	Mar. 13
Silence Therapeutics' 2023 Loss Narrows, Revenue Rises	Mar. 13	MT
Silence Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Silence Therapeutics plc Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(A)	Mar. 13	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	Mar. 12	MT
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading	Mar. 11	MT
European Equities Traded in the US as American Depositary Receipts Rise Thursday	Mar. 07	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Feb. 28	MT
European Equities Traded in the US as American Depositary Receipts Rise Friday, Set to End Week Up 1.5%	Feb. 23	MT

Chart Silence Therapeutics plc

Duration

Period

More charts

Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is focused on discovering and developing molecules incorporating short-interfering ribonucleic acid (siRNA) to inhibit the expression of target genes in the pathology of diseases with unmet medical need. Its siRNA molecules are designed to harness the body's natural mechanism of RNA interference (RNAi), by specifically binding to and degrading messenger RNA (mRNA), molecules that encode specific targeted disease-associated proteins in a cell. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform is a platform of precision-engineered medicines designed to target disease-associated genes in the liver. Its wholly owned product candidates include SLN360, for the unmet need in reducing cardiovascular risk in people born with high Lipoprotein (a) levels and SLN124, for rare hematological conditions, including thalassemia, myelodysplastic syndrome (MDS), and polycythemia vera (PV).

Sector

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company